I Ask This Of You!
I have Parkinson's diseases and thought it would be nice to have a place where the contents of updated news is found in one place. That is why I began this blog.
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible.
I am not responsible for it's contents. I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish.
This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns.
Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. I will not accept any information about Herbal treatments curing Parkinson's, dementia and etc. It will go into Spam.
This is a free site for all with no advertisements.
Thank you for visiting!
Saturday, May 13, 2017
Friday, May 12, 2017
May 12, 2017 Suzanne Elvidge
- Adamas Pharmaceuticals has entered into an agreement with HealthCare Royalty Partners (HCR) in an effort to get some quick cash so that it can continue development of its pipeline.
- Under the terms of the agreement, Adamas will get $35 million upfront and then another $65 million when the Food and Drug Administration approves Parkinson's drug ADS-5102 and gives it orphan Drug exclusivity. The drug is currently under review and has a user fee action date of August 24.
- Adamas will use the proceeds from the royalty deal to pay for general
- expenses, as well as the commercialization of ADS-5102.